Ray Therapeutics Secures $125 Million in Series B Funding
Ray Therapeutics, a gene therapy company based in Berkeley, California, has announced the successful closure of its Series B funding round, raising $125 million. The round was led by Janus Henderson Investors, with participation from a diverse group of investors including 4BIO Capital, Adage Capital Management, Deerfield Management, Franklin Templeton, Invus, Marshall Wace, MRL Ventures Fund, Norwest, Novo Holdings A/S, and Platanus.
Company Overview
Ray Therapeutics is focused on developing gene therapies aimed at treating and potentially curing degenerative retinal diseases. The company is led by Co-Founder and CEO Paul Bresge, who is at the forefront of its mission to innovate treatments that can restore vision for patients suffering from these debilitating conditions.
Strategic Use of Funds
The newly acquired funds are expected to be utilized for advancing the company's research and development efforts. Specifically, Ray Therapeutics plans to accelerate the clinical trials of its lead gene therapy candidates, which are designed to address unmet medical needs in the field of ophthalmology. The funding will also support expanding the company's team and infrastructure to enhance its capabilities in delivering cutting-edge therapies.
Investor Confidence
The participation of prominent investors underscores the confidence in Ray Therapeutics' potential to make significant strides in the treatment of retinal diseases. The involvement of Janus Henderson Investors as the lead investor highlights the strategic interest in supporting innovative biotech solutions.
Leadership Perspective
Paul Bresge, CEO of Ray Therapeutics, expressed his commitment to advancing the company's therapeutic programs. While specific quotes from Bresge were not available, his leadership is instrumental in driving the company's vision forward.
Conclusion
With this substantial Series B funding, Ray Therapeutics is well-positioned to continue its work in gene therapy, with the potential to transform the treatment landscape for retinal diseases. The support from a robust group of investors reflects a strong belief in the company's innovative approach and future prospects.